drugset / Trial / NCT01948791

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

NCT01948791

Phase 4 Completed 222 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration

Timeline

Start
2014-08
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule

Indications